Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & American Society of Clinical Oncology

13 shared events · Importance 4 · Last updated Jun 12, 2026

Importance
4
Shared Events
13
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
65
Tech
United States — Food and Drug Administration: FDA granted Breakthrough Device Designation to SPOT-MAS 10, a non-approval milestone that facilitates regulatory review.
American Society of Clinical Oncology: ASCO highlighted the study in its press center and Science in Seconds, lending credibility to the technology.
Jul 06, 2026 · 6 articles
49
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.
American Society of Clinical Oncology: The American Society of Clinical Oncology meeting in Chicago was the venue where the significant findings of the daraxonrasib study were presented to the medical community.
May 29, 2026 · 74 articles
45
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
American Society of Clinical Oncology: ASCO hosted the presentation of the pivotal trial results, which received a standing ovation, highlighting the significance of the data.
Aug 26, 2026 · 92 articles
40
Regulatory
United States — Food and Drug Administration: The FDA accepted the NDA for review and will decide on approval by April 28, 2027, playing a critical regulatory role in the event.
American Society of Clinical Oncology: The RINGSIDE trial results were presented at the 2026 ASCO Annual Meeting, providing a platform for data dissemination.
Jul 08, 2026 · 6 articles
40
Tech
United States — Food and Drug Administration: The FDA is the regulatory authority that must approve the vaccine. Approval could come as soon as 2027, but the agency's review process and potential political interference from the administration could affect the timeline.
American Society of Clinical Oncology: ASCO's chief medical officer called the trial a 'monumental leap forward,' validating mRNA technology. The society may see increased engagement and research in this area.
Aug 19, 2026 · 126 articles
24
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) has granted two Fast Track Designations to IBI363, indicating its potential to address unmet medical needs and expedite its development and review process.
American Society of Clinical Oncology: The American Society of Clinical Oncology (ASCO) Annual Meeting is the platform where the updated clinical data for IBI363 was presented, providing a significant forum for disseminating these important findings to the medical and scientific community.
May 21, 2026 · 9 articles
24
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) granted Fast Track Designation to golidocitinib in February 2022, accelerating its development pathway in the US.
American Society of Clinical Oncology: The American Society of Clinical Oncology (ASCO) Annual Meeting served as the platform for Dizal Pharmaceutical to present its clinical trial results, providing a credible forum for dissemination.
May 31, 2026 · 6 articles
17
Tech
United States — Food and Drug Administration: Mentioned only in a headline reference; no direct role in the study.
American Society of Clinical Oncology: Hosted the presentation of the study's findings at its 2025 annual meeting.
Sep 03, 2026 · 23 articles
14
Business
United States — Food and Drug Administration: FDA received sNDA for first-line Zegfrovy and granted Breakthrough Therapy Designation.
American Society of Clinical Oncology: ASCO hosted presentation of WU-KONG28 trial results as a Late-Breaking Abstract.
Jul 14, 2026 · 8 articles
14
Business
United States — Food and Drug Administration: The FDA approved Celcuity's product REVTORPYK, which is mentioned in the announcement. The event does not involve new FDA actions, but the approval is part of the company's background.
American Society of Clinical Oncology: ASCO is mentioned as the venue where results from the VIKTORIA-1 trial were presented. The event does not involve new ASCO actions, but the presentation is part of the company's clinical development history.
Aug 06, 2026 · 6 articles
0
Business
May 14, 2026 · 6 articles
0
Tech
May 12, 2026 · 6 articles
0
Business
May 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and American Society of Clinical Oncology interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.